Bernhard Ellinger
Overview
Explore the profile of Bernhard Ellinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linciano P, Quotadamo A, Luciani R, Santucci M, Zorn K, Foil D, et al.
J Med Chem
. 2023 Nov;
66(22):15230-15255.
PMID: 37921561
Broad-spectrum anti-infective chemotherapy agents with activity against , and species were identified from a high-throughput phenotypic screening program of the 456 compounds belonging to the Ty-Box, an in-house industry database....
2.
Zheng Y, van den Kerkhof M, van der Meer T, Gul S, Kuzikov M, Ellinger B, et al.
J Med Chem
. 2023 Jul;
66(15):10252-10264.
PMID: 37471520
Human African Trypanosomiasis (HAT), caused by , is one of the neglected tropical diseases with a continuing need for new medication. We here describe the discovery of 5-phenylpyrazolopyrimidinone analogs as...
3.
Roussaki M, Magoulas G, Fotopoulou T, Santarem N, Barrias E, Pohner I, et al.
Bioorg Chem
. 2023 May;
138:106615.
PMID: 37244229
A series of nine novel ether phospholipid-dinitroaniline hybrids were synthesized in an effort to deliver more potent antiparasitic agents with improved safety profile compared to miltefosine. The compounds were evaluated...
4.
Iaconis D, Caccuri F, Manelfi C, Talarico C, Bugatti A, Filippini F, et al.
Viruses
. 2023 May;
15(5).
PMID: 37243214
During the COVID-19 pandemic, drug repurposing represented an effective strategy to obtain quick answers to medical emergencies. Based on previous data on methotrexate (MTX), we evaluated the anti-viral activity of...
5.
Ruzic D, Ellinger B, Djokovic N, Santibanez J, Gul S, Beljkas M, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559094
Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors...
6.
Zaliani A, Vangeel L, Reinshagen J, Iaconis D, Kuzikov M, Keminer O, et al.
Sci Data
. 2022 Jul;
9(1):405.
PMID: 35831315
Worldwide, there are intensive efforts to identify repurposed drugs as potential therapies against SARS-CoV-2 infection and the associated COVID-19 disease. To date, the anti-inflammatory drug dexamethasone and (to a lesser...
7.
Pohner I, Quotadamo A, Panecka-Hofman J, Luciani R, Santucci M, Linciano P, et al.
J Med Chem
. 2022 Jun;
65(13):9011-9033.
PMID: 35675511
The optimization of compounds with multiple targets is a difficult multidimensional problem in the drug discovery cycle. Here, we present a systematic, multidisciplinary approach to the development of selective antiparasitic...
8.
Kuzikov M, Woens J, Zaliani A, Hambach J, Eden T, Fehse B, et al.
Biomed Pharmacother
. 2022 Jun;
151:113104.
PMID: 35643072
The Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) has continuously evolved, resulting in the emergence of several variants of concern (VOCs). To study mechanisms of viral entry and potentially...
9.
Jarzina S, Di Fiore S, Ellinger B, Reiser P, Frank S, Glaser M, et al.
Front Toxicol
. 2022 May;
4:864441.
PMID: 35516525
Application of adverse outcome pathways (AOP) and integration of quantitative to extrapolation (QIVIVE) may support the paradigm shift in toxicity testing to move from apical endpoints in test animals to...
10.
Lage-Rupprecht V, Schultz B, Dick J, Namysl M, Zaliani A, Gebel S, et al.
Patterns (N Y)
. 2022 May;
3(3):100433.
PMID: 35510183
The high number of failed pre-clinical and clinical studies for compounds targeting Alzheimer disease (AD) has demonstrated that there is a need to reassess existing strategies. Here, we pursue a...